European Parliament 20 July 2012, Written question E-007346/12 Alyn Smith (Verts/ALE) to the Commission. Ivacaftor product licence

Question for written answer E-007346/12 to the Commission Alyn Smith (Verts/ALE) (20 July 2012) Subject: Ivacaftor product licence On 24 May 2012 the European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion (237) in respect of a new drug for the treatment of cystic fibrosis called ivacaftor (brand name Kalydeco).